Cited by 184Schizophrenia research and treatmentNeuroscience and Neuropharmacology ResearchNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.

Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications

Open access

Coyle, Joseph T., Basu, Alo, Benneyworth, Michael, Balu, Darrick, Konopaske, Glenn·2012·Handbook of Experimental Pharmacology

DOI 10.1007/978-3-642-25758-2_10PMC PMC4817347

Open this paper in CoChat — free account

Abstract

Schizophrenia affects approximately 1% of the population and continues to be associated with poor outcome because of the limited efficacy of and noncompliance with existing antipsychotic medications. An alternative hypothesis invoking the excitatory neurotransmitter, glutamate, arose out of clinical observations that NMDA receptor antagonists, the dissociative anesthetics like ketamine, can replicate in normal individuals the full range of symptoms of schizophrenia including psychosis, negative symptoms, and cognitive impairments. Low dose ketamine can also re-create a number of physiologic abnormalities characteristic of schizophrenia. Postmortem studies have revealed abnormalities in endogenous modulators of NMDA receptors in schizophrenia as well as components of a postsynaptic density where NMDA receptors are localized. Gene association studies have revealed several genes that affect NMDA receptor function whose allelic variants are associated with increased risk for schizophrenia including genes encoding D-amino acid oxidase, its modulator G72, dysbindin, and neuregulin. The parvalbumin-positive, fast-firing GABAergic interneurons that provide recurrent inhibition to cortical-limbic pyramidal neurons seem to be most sensitive to NMDA receptor hypofunction. As a consequence, disinhibition of glutamatergic efferents disrupts cortical processing, causing cognitive impairments and negative symptoms, and drives subcortical dopamine release, resulting in psychosis. Drugs designed to correct the cortical-limbic dysregulated glutamatergic neurotransmission show promise for reducing negative and cognitive symptoms of schizophrenia as well as its positive symptoms.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/978-3-642-25758-2_10

Cites

216 of 216 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Glycine potentiates the NMDA response in cultured mouse brain neurons
Johnson, J. W., & Ascher, P. (1987) · Nature · doi:10.1038/325529a0 · Cited by 3,182
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies
BRAFF, D. L., Geyer, M. A., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100810 · Cited by 1,701
Decreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636
Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review
Geyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484
Rare chromosomal deletions and duplications increase risk of schizophrenia
The International Schizophrenia Consortium (2008) · Nature · doi:10.1038/nature07239 · Cited by 1,475
Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
Whitfield-Gabrieli, S., Thermenos, H. W., Milanovic, S., Tsuang, M. T., Faraone, S. V., McCarley, R. W., Shenton, M. E., Green, A. I., Nieto-Castanon, A., LaViolette, P., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809141106 · Cited by 1,435

Show all 216 references

Sorted by citations

Items 101–184 of 184

Sarcosine (glycine transporter inhibitor) attenuates behavioural and biochemical changes induced by ketamine, in the rat model of schizophrenia
Kumar, A., Akhtar, A., Kuhad, A., & Sah, S. P. (2022) · Experimental Brain Research · doi:10.1007/s00221-022-06530-4 · Cited by 15
Parvalbumin Loss Following Chronic Sub-Anesthetic NMDA Antagonist Treatment is Age-Dependent in the Hippocampus: Implications for Modeling NMDA Hypofunction
Honeycutt, J. A., & Chrobak, J. J. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.09.031 · Cited by 15
Changes in the expression of metabotropic glutamate receptor 5 (mGluR5) in a ketamine-based animal model of schizophrenia
Żurawek, D., Salerno-Kochan, A., Dziedzicka‐Wasylewska, M., Nikiforuk, A., Kos, T., & Popik, P. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.04.014 · Cited by 14
Abnormalities of the glutamine–glutamate–GABA cycle in the schizophrenia brain
Hashimoto, K. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.04.008 · Cited by 14
Micronization of naringenin in supercritical fluid medium: In vitro and in vivo assays
de Oliveira, P. V., Sanaiotto, O., Kuhn, K. Z., Oltramari, A. R., Bortoluzzi, A. J., Lanza, M., Aguiar, G. P. S., Siebel, A. M., Müller, L. G., & de Oliveira, J. V. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104382 · Cited by 13
Biomarkers for Antipsychotic Therapies
Pich, E. M., Vargas, G. A., & Domenici, E. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25761-2_13 · Cited by 13
Glutamate Concentration in the Serum of Patients with Schizophrenia
Ivanova, S. А., Boyko, A. S., Fedorenko, O. Y., Михайловна, К. Н., Semke, A. V., & Bokhan, N. A. (2014) · Procedia Chemistry · doi:10.1016/j.proche.2014.10.015 · Cited by 12
Neurobiological Insights from mGlu Receptor Allosteric Modulation
O’Brien, D. E., & Conn, P. J. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv133 · Cited by 12
Axonal Type III Nrg1 Controls Glutamate Synapse Formation and GluA2 Trafficking in Hippocampal-Accumbens Connections
Zhong, C., Akmentin, W., Du, C., Role, L. W., & Talmage, D. A. (2017) · eNeuro · doi:10.1523/eneuro.0232-16.2017 · Cited by 11
DHF-7 Ameliorates Behavioral Disorders and White Matter Lesions by Regulating BDNF and Fyn in a Mouse Model of Schizophrenia Induced by Cuprizone and MK-801
Sun, Z., Ma, D., Gu, L.-H., Chen, X., Zhang, L., & Li, L. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac022 · Cited by 11
Managing electromyogram contamination in scalp recordings: An approach identifying reliable beta and gamma EEG features of psychoses or other disorders
Pope, K. J., Lewis, T. W., Fitzgibbon, S. P., Janani, A. S., Grummett, T. S., Williams, P. A. H., Battersby, M., Bastiampillai, T. J., Whitham, E. M., & Willoughby, J. O. (2022) · Brain and Behavior · doi:10.1002/brb3.2721 · Cited by 10
Loss of Dysbindin Implicates Synaptic Vesicle Replenishment Dysregulation as a Potential Pathogenic Mechanism in Schizophrenia
Hu, H., Wang, X., Li, C., Li, Y., Hao, J., Zhou, Y., Yang, X., Chen, P., Shen, X., & Zhang, S. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.10.020 · Cited by 10
Levels of the Rab GDP dissociation inhibitor (GDI) are altered in the prenatal restrain stress mouse model of schizophrenia and are differentially regulated by the mGlu2/3 receptor agonists, LY379268 and LY354740
Orlando, R., Borro, M., Motolese, M., Molinaro, G., Scaccianoce, S., Caruso, A., di Nuzzo, L., Caraci, F., Matrisciano, F., Pittaluga, A., et al. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.009 · Cited by 10
Endogenous co-agonists of the NMDA receptor modulate contextual fear in trace conditioning
Basu, A. C., Puhl, M. D., & Coyle, J. T. (2016) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2016.09.006 · Cited by 10
Self-citation
Receptor-Mediated AKT/PI3K Signalling and Behavioural Alterations in Zebrafish Larvae Reveal Association between Schizophrenia and Opioid Use Disorder
Thiagarajan, S. K., Mok, S. Y., Ogawa, S., Parhar, I. S., & Tang, P. Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094715 · Cited by 9
Using iPSC Models to Understand the Role of Estrogen in Neuron–Glia Interactions in Schizophrenia and Bipolar Disorder
de Assis, D. R., Szabó, A., Osete, J. R., Puppo, F., O’Connell, K. S., Akkouh, I. A., Hughes, T., Frei, E., Andreassen, O. A., & Djurovic, S. (2021) · Cells · doi:10.3390/cells10020209 · Cited by 10
MGlur5 Positive Allosteric Modulation Prevents MK-801 Induced Increases in Extracellular Glutamate in the Rat Medial Prefrontal Cortex
LaCrosse, A., May, C. E., Griffin, W. C., & Olive, M. F. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.06.016 · Cited by 8
Effects of combined postweaning social isolation and ketamine administration on schizophrenia-like behaviour in male Sprague Dawley rats
Shangase, K. B., Luvuno, M., & Mabandla, M. V. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115214 · Cited by 8
Parvalbumin-positive GABAergic interneurons deficit in the hippocampus in Gunn rats: A possible hyperbilirubinemia-induced animal model of schizophrenia
Hayashida, M., Miyaoka, T., Tsuchie, K., Araki, T., Izuhara, M., Miura, S., Kanayama, M., Ohtsuki, K., Nagahama, M., Azis, I. A., et al. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02037 · Cited by 8
Mutant Mouse Models in Evaluating Novel Approaches to Antipsychotic Treatment
O’Tuathaigh, C. M. P., Desbonnet, L., & Waddington, J. L. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_5 · Cited by 8
Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia
Conde-Ceide, S., Alcázar, J., de Diego, S. A. A., López, S., Martı́n-Martı́n, M. L., Martínez‐Viturro, C. M., Pena, M. A., Tong, H. M., Lavreysen, H., Mackie, C. E., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.11.098 · Cited by 8
The effect of rs1076560 (DRD2) and rs4680 (COMT) on tardive dyskinesia and cognition in schizophrenia subjects
Punchaichira, T. J., Kukshal, P., Triptish Bhatia, A., Deshpande, S. N., & Thelma, B. K. (2020) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000258 · Cited by 7
Pregestational Exposure to T. gondii Produces Maternal Antibodies That Recognize Fetal Brain Mimotopes and Induces Neurochemical and Behavioral Dysfunction in the Offspring
Núñez, E. R., Blanco-Ayala, T., Cervantes, G. I. V., Roldán-Roldán, G., González-Esquivel, D., Muñiz-Hernández, S., Salazar, A., Armenta, M. M., Gómez-Manzo, S., González-Conchillos, H., et al. (2022) · Cells · doi:10.3390/cells11233819 · Cited by 6
Developing a risk assessment model for treatment-resistant schizophrenia: The role of niacin receptor GPR109A and prostaglandin receptors DP1, EP2, and EP4 in the niacin-induced flushing pathway
Chiu, C.-W., Chen, B.-Y., Lin, J., Tseng, H., Huang, C., Wang, T., Jang, F.-L., Yao, C.-Y., Chang, W. H., Chen, P.-S., et al. (2025) · Schizophrenia Research · doi:10.1016/j.schres.2025.04.003 · Cited by 7
Near-Death Experiences: Actual Considerations
Charland‐Verville, V., Martial, C., Cassol, H., & Laureys, S. (2017) · Springer eBooks · doi:10.1007/978-3-319-55964-3_14 · Cited by 7
Interneuron Heterotopia in the Lis1 Mutant Mouse Cortex Underlies a Structural and Functional Schizophrenia-Like Phenotype
García‐López, R., Pombero, A., Estirado, A., Geijo‐Barrientos, E., & Martı́nez, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.693919 · Cited by 7
Homozygous Deletion of Glutathione Peroxidase 1 and Aldehyde Dehydrogenase 1a1 Genes Is Not Associated with Schizophrenia-Like Behavior in Mice.
Bai, X., Fermandez, E., Gould, G. G., & Strong, R. (2013) · PubMed · Cited by 7
Ketamine-assisted psychotherapies for mental disorders: A historical overview and systematic review
Veraart, J. K. E., Schimmers, N., Breeksema, J. J., Seybert, C., Kamphuis, J., Huber, L. F. T., Rota, A., Coerts, D. T., Oliveira-Maia, A. J., & Schoevers, R. A. (2026) · Clinical Psychology Review · doi:10.1016/j.cpr.2026.102706 · Cited by 7
Connecting Brain Proteomics with Behavioural Neuroscience in Translational Animal Models of Neuropsychiatric Disorders
Sarnyai, Z., & Guest, P. C. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-52479-5_6 · Cited by 6
Association between genetic variability of neuronal nitric oxide synthase and sensorimotor gating in humans
Rovný, R., Marko, M., Katina, S., Murínová, J., Roháriková, V., Cimrová, B., Repiská, G., Minárik, G., & Riečanský, I. (2018) · Nitric Oxide · doi:10.1016/j.niox.2018.08.002 · Cited by 7
Induced pluripotent stem cell models for advancing neurodevelopmental disorder research and regenerative medicine: a narrative review
Naffaa, M. M. (2025) · Regenerative medicine reports . · doi:10.4103/regenmed.regenmed-d-25-00013 · Cited by 5
Effects of NMDA antagonists on the development and expression of tolerance to diazepam-induced motor impairment in mice
Talarek, S., Orzelska‐Górka, J., Listos, J., Serefko, A., Poleszak, E., & Fidecka, S. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.12.009 · Cited by 5
14-3-3 proteins at the crossroads of neurodevelopment and schizophrenia
Antunes, A. S. L. M., Saia-Cereda, V. M., Crunfli, F., & Martins‐de‐Souza, D. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2021.1925585 · Cited by 5
Pediatric anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: Exploring psychosis, related risk factors, and hospital outcomes in a nationwide inpatient sample: A cross-sectional study
Jaka, S., Singh, S., Vashist, S., Pokhrel, S., Saldana-Rodriguez, E. A., Sejdiu, A., Taneja, S., Arisoyin, A. E., Mogallapu, R., Gunturu, S., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0296870 · Cited by 5
miRNA-Based Diagnosis of Schizophrenia Using Machine Learning
Heda, V., Dogra, S., Kouznetsova, V. L., Kumar, A., Kesari, S., & Tsigelny, I. F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052280 · Cited by 5
Near-Death Experiences: What Do We Know?
Fritz, P., Lejeune, N., Cassol, H., Laureys, S., Gosseries, O., & Martial, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-50563-8_13 · Cited by 6
Eosinophils and Cognitive Impairment in Schizophrenia: A New Perspective
Obeagu, E. I., & Bluth, M. H. (2024) · Journal of Blood Medicine · doi:10.2147/jbm.s451988 · Cited by 4
Microglial Gene Expression Alterations in the Brains of Patients with Psychiatric Disorders
Sakai, M., Takahashi, Y., Yu, Z., & Tomita, H. (2016) · Advances in Neuroimmune Biology · doi:10.3233/nib-160110 · Cited by 4
Neuronal pentraxin-2 (NPTX2) serum levels during an acute psychotic episode in patients with schizophrenia
Göverti, D., Büyüklüoğlu, N., Kaya, H., Yüksel, R. N., Yücel, Ç., & Göka, E. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06147-z · Cited by 5
Lack of association of SLC1A1 variants with schizophrenia in Chinese Han population
Lu, W., Wu, H., Cai, J., Wang, Z., Yi, Z., Yu, S., Fang, Y., & Zhang, C. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.07.009 · Cited by 4
Naringin processing using GAS antisolvent technique and in vivo applications
de Oliveira, P. V., Dias, J. L., Sakata, G. S. B., Aguiar, G. P. S., Kuhn, K. Z., Sanaiotto, O., Provinelli, A. C., Daniel, C., Bortoluzzi, A. J., Precisvalle, N., et al. (2023) · The Journal of Supercritical Fluids · doi:10.1016/j.supflu.2023.106148 · Cited by 3
Postnatal functional inactivation of the ventral subiculum enhances dopaminergic responses in the core part of the nucleus accumbens following ketamine injection in adult rats
Saoud, H., de Beus, D., Eybrard, S., & Louilot, A. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104736 · Cited by 3
Sex-specific behavioral impairments produced by neonatal exposure to MK-801 are partially reversed by adolescent CDPPB treatment
Miller‐Rhodes, P., Piazza, N., Mattle, A. G., Teboul, E., Ehmann, M., Morris‐Schaffer, K., & Markowski, V. P. (2021) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2021.107053 · Cited by 3
Probing the biological consequences of a previously undescribed de novo mutation of ZMYND11 in a schizophrenia patient by CRISPR genome editing and induced pluripotent stem cell based in vitro disease-modeling
Tordai, C., Hathy, E., Gyergyák, H., Vincze, K., Baradits, M., Koller, J., Póti, Á., Jezsó, B., Homolya, L., Molnár, M. J., et al. (2024) · Schizophrenia Research · doi:10.1016/j.schres.2024.01.024 · Cited by 3
Advances in neuroimaging research of schizophrenia in China.
Liu, D., Xu, Y., & Jiang, K. (2014) · PubMed Central · doi:10.3969/j.issn.1002-0829.2014.04.002 · Cited by 3
Effect of D-serine on Anxiety-like Behavior and Spatial Learning Ability in GC Rats Selected for the Predisposition to Catatonic Reactions
Prokudina, O. I., & Alekhina, T. A. (2021) · Journal of Evolutionary Biochemistry and Physiology · doi:10.1134/s0022093021060077 · Cited by 3
The Long-Term Effect of Schizophrenia on the Brain: Dementia Praecox?
Sweeney, J. A. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030413 · Cited by 3
Cannabidiol, but Not Δ9-Tetrahydrocannabinol, Has Strain- and Genotype-Specific Effects in Models of Psychosis
Mielnik, C. A., Li, C. K., Ramsey, A. J., Salahpour, A., Burnham, W. M., & Ross, R. A. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0125 · Cited by 2
Deciphering the landscape of lncRNA-driven ceRNA network in schizophrenia etiology
Mukhopadhyay, A., Singh, P. K., Dohare, R., & Thelma, B. K. (2024) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-024-00542-1 · Cited by 2
The Relationship of glutamate signaling to cannabis use and schizophrenia
Niznikiewicz, M. A., Lin, A. P., & DeLisi, L. E. (2025) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000001003 · Cited by 3
Functional Analysis of Antipsychotics in Human iPSC-Based Neural Progenitor 2D and 3D Schizophrenia Models
Farkas, K. G., Vincze, K., Tordai, C., Özgen, E. İ., Gürler, D., Deli, V., Lilienberg, J., Erdei, Z., Sarkadi, B., Réthelyi, J., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094444 · Cited by 2
Ketamine abusers with SLC6A3 rs393795 genotype showed a preliminary association with psychosis and schizophrenia: A pilot case-control study
Chung, A. K.-K., Chan, W.-M., Law, J. K. C., & Tse, C. Y. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.02.014 · Cited by 2
Differential Effects of Chronic Methamphetamine Treatment on High-Frequency Oscillations and Responses to Acute Methamphetamine and NMDA Receptor Blockade in Conscious Mice
Hudson, M., Foreman, J., Rind, G. S., Manning, E., Jones, N. C., & van den Buuse, M. (2022) · Brain Sciences · doi:10.3390/brainsci12111503 · Cited by 2
The Ketogenic Diet in the Treatment of Schizophrenia
Sarnyai, Z., Kraeuter, A.-K., & Palmer, C. M. (2022) · Oxford University Press eBooks · doi:10.1093/med/9780197501207.003.0020 · Cited by 1
Human-Induced Pluripotent Stem Cells are a Unique Approach for Modeling Schizophrenia: Calcium Homeostasis
Nazari-Serenjeh, F., Ghadikolaii, N. L., Mohsenipour, S., & Ghasemzadeh, Z. (2022) · The Neuroscience Journal of Shefaye Khatam · doi:10.52547/shefa.10.3.98 · Cited by 1
Actions of Drugs on The Brain and CNS Disorders
Blackburn, T. P. (2017) · Royal Society of Chemistry eBooks · doi:10.1039/bk9781782621423-00130 · Cited by 1
The Fog of Schizophrenia: Cognitive Impairments and Their Impact on Daily Life
Stănculete, M. F., & Căpățînă, O. (2025) · IntechOpen eBooks · doi:10.5772/intechopen.1009278 · Cited by 1
Change in expression of vesicular protein synapsin II by chronic treatment with D2 allosteric modulator PAOPA
Basu, D., Tian, Y., Hui, P., Bhandari, J., Johnson, R. L., & Mishra, R. K. (2015) · Peptides · doi:10.1016/j.peptides.2015.01.004 · Cited by 1
The use of adjuvant L-arginine in schizophrenia: A behavioural and neurochemical analysis
MacKay, M.-A. B. (2016) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3zs2kq4m · Cited by 1
Evaluating Novel Muscarinic Acetylcholine Receptor Potentiators for the Treatment of Cognitive Deficits in Schizophrenia
Grannan, M. D. (2016) · Cited by 1
University Medical School of Naples "Federico II" Department of Neuroscience, Reproductive and Odontostomatologic Sciences
Annunziato, L. (2013)
Glutamate Signaling in Benign and Malignant Disorders: Current Status, Future Perspectives, and Therapeutic
Willard, I. S., & Koochekpour, S. (2013)
Einfluss von Polymorphismen im DTNBP1-Gen auf die Ausprägung von Persönlichkeitseigenschaften im STAXI
Falkai, P. (2014)
My Life in Clinical Neuroscience
COYLE, J. T. (2016) · Advances in pharmacology · doi:10.1016/bs.apha.2016.02.002
Self-citation
Schizophrenie und oxidativer Stress: Veränderungen des antioxidativen Schutzsystems (AODS) bei erst- und wiedererkrankten unbehandelten Patienten
Neuhaus, D. (2015) · Common Library Network (Der Gemeinsame Bibliotheksverbund)
2.4 Brain Neurochemistry and Cognitive Performance: Neurotransmitter Systems
Lobo, A. C., & Summavielle, T. (2015) · doi:10.1515/9783110468755-006 · Cited by 1
Postnatal functional inactivation of the ventral subiculum enhances dopaminergic responses in the core part of the nucleus accumbens following ketamine injection in adult ratsPreprint
Saoud, H., de Beus, D., Eybrard, S., & Louilot, A. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/859322
Transparent Machine Learning for Multi-Omics Analysis of Mental Disorders
Belin, S. (2020) · Uppsala University Publications (Uppsala University)
Magnetic Resonance Spectroscopy Studies in Schizophrenia
Öngür, D. (2020) · Springer eBooks · doi:10.1007/978-3-030-35206-6_10
Association of Glutamate Receptor Metabotropic 5 Gene (Grm5) Polymorphisms With Schizophrenia Susceptibility and Symptoms in a Chinese-Han PopulationPreprint
Li, W., Su, X., Guo, X., Liu, Q., Zhang, L., Shao, M., Zhang, Y., Ding, M., Lu, Y., Yang, Y., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-253495/v1
[Cerebrospinal venous insufficiency as a cause of MS weakly supported. Unreasonable to offer balloon dilatation therapy now].
Bergqvist, D., & Wanhainen, A. (2011) · PubMed
Developmental Manipulation-Induced Changes in Cognitive Functioning
Kaki, S., DeRosa, H., Timmerman, B. M., Brummelte, S., Hunter, R. G., & Kentner, A. C. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_389
Prodromes and biological markers in schizophrenia: Importance for the dopamine, glutamate, and neurodevelopmental hypothesis
Díaz-Sánchez, J. P., Solís‐Chagoyán, H., & Benítez‐King, G. (2022) · Salud Mental · doi:10.17711/sm.0185-3325.2022.033 · Cited by 1
The ketogenic diet in schizophrenia
ĆWIEK, M., Bigdoń, A. M., Gorczyca, P., GÓRA, M., Hunek, A. K., Kozłowska, M., Kreft, R., SYDOR, P., WARTACZ, M., & Woźniak, A. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.43.01.012
Cognitive function differences across subtypes of first-episode antipsychotic-naïve schizophrenia: insights from event-related potentials
Lu, C., Li, S., Zhang, X., Han, Y., Wang, L., Sun, W., Zhang, C., Wang, S., Li, S., Li, J., et al. (2026) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-026-02221-1
Chronic Co-administration of Methylphenidate and Fluoxetine Reduces Striatal NMDA Receptor Binding in Adolescent Rats
Lagamjis, G., Slayton, D., Lu, H., Hoerner, C., Lantry, A. M., Marion, M., Elman, D. J., Hadjiargyrou, M., Komatsu, D. E., & Thanos, P. K. (2026) · Neurochemical Research · doi:10.1007/s11064-026-04743-5
Cerebral metabolism as an isolated predictor of 50% symptomatic improvement over 12 weeks of acute psychotic episode treatment in schizophrenia
Donicz, P., Krzyściak, W., Szwajca, M., Śmierciak, N., Bryll, A., Karcz, P., Rozynek, M., Popiela, T., Silverstein, S. M., & Pilecki, M. W. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.04.021
Machine learning-based morphological brain analysis in schizophrenia and unaffected siblings: a multisite study of potential risk markers
Manabu, I., Tanigaki, K., Ogawa, N., Nitta, N., & Shiino, A. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1688282
GRIA Gene Expression in Schizophrenia: A Participant-Level Meta-Analysis
Baumel, A., Yitzhaky, A., & Hertzberg, L. (2026) · ALPHA PSYCHIATRY · doi:10.31083/ap46200
Systematic characterization of subchronic MK-801 administration across mouse strains identifies conserved synaptic alterations and a clear cognitive phenotype in C57BL/6J mice
Yoshimachi, F., Ikuta, M., Kimura, K., Wang, H., Fu, J., Kirikae, H., Kumar, A., Shima, Y., Yamamoto, Y., Miyazaki, H., et al. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111921
BindingDB Entry 50018507: Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress.
BindingDB (2024) · UC San Diego · doi:10.7270/q2bp070h
BindingDB Entry 50046861: Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia.
BindingDB (2017) · UC San Diego · doi:10.7270/q2sj1ngs
BindingDB Entry 50014969: Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia.
BindingDB (2023) · UC San Diego · doi:10.7270/q25x2dsh
BindingDB Entry 50044160: Design, synthesis, and structure-activity relationship of a novel series of GluN2C-selective potentiators.
BindingDB (2015) · UC San Diego · doi:10.7270/q2sb4786

Authors: Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G.
Affiliations: Harvard University (US)
Corresponding author: Coyle, Joseph T.
ORCID: Coyle, Joseph T.
Benneyworth, Michael
Balu, Darrick
Venue: Handbook of Experimental Pharmacology
Publisher: Springer Berlin Heidelberg
Published: 2012
Issue: 213
Pages: 267-295
ISSN: 0171-2004 (ISSN-L)
1865-0325
DOI: 10.1007/978-3-642-25758-2_10
PMC: PMC4817347
OpenAlex: W1872072116
Cited by: 180
References: 216
Citations by year: 2026: 7 · 2025: 7 · 2024: 6 · 2023: 4 · 2022: 13 · 2021: 19 · 2020: 10 · 2019: 9 · 2018: 10 · 2017: 11 · 2016: 11 · 2015: 21 · 2014: 25 · 2013: 22 · 2012: 4
FWCI: 81.63
Type: book chapter
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Handbook of experimental pharmacology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: U.S. Public Health Service
National Institute of Mental Health (P50MH060450, R01 MH51290, R01MH051290, F32MH090697, P50MH06045)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: schizophrenia, NMDA receptor hypofunction, ketamine, dissociative anesthetics, postsynaptic density, D-amino acid oxidase, G72, dysbindin, neuregulin, parvalbumin interneurons, cognitive impairment, negative symptoms, psychosis, dopamine release, glutamatergic neurotransmission
MeSH terms: Animals, Cognition, gamma-Aminobutyric Acid, Humans, Ketamine, Synaptic Transmission, Schizophrenia, Synapses, Receptors, N-Methyl-D-Aspartate, Glutamic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks